ZFIN ID: ZDB-FISH-161027-2
|
Fish name:
|
s705Tg
|
Genotype: |
s705Tg
|
Targeting Reagent: |
none
|
HUMAN DISEASE MODELED by s705Tg
No data available
GENE EXPRESSION
Gene expression in s705Tg
Protein expression
Antibody
|
Antigen Genes
|
Structure
|
Conditions
|
Figures
|
Ab9-rps6
|
|
|
control
|
Fig. 6
from Cox et al., 2016
|
Ab11-akt
|
|
|
control
|
Fig. 6
from Cox et al., 2016
|
Ab11-akt
|
|
|
chemical treatment: sirolimus
|
Fig. 6
from Cox et al., 2016
|
Ab9-rps6
|
|
|
chemical treatment: sirolimus
|
Fig. 6
from Cox et al., 2016
|
Ab5-akt
|
|
|
chemical treatment: sirolimus
|
Fig. 6
from Cox et al., 2016
|
Ab5-rps6
|
|
|
control
|
Fig. 6
from Cox et al., 2016
|
Ab6-pcna
|
|
|
control
|
Fig. 7
from Cox et al., 2016
|
Ab5-akt
|
|
|
control
|
Fig. 6
from Cox et al., 2016
|
Ab5-rps6
|
|
|
chemical treatment: sirolimus
|
Fig. 6
from Cox et al., 2016
|
Ab6-pcna
|
|
|
chemical treatment: methionine sulfoximine
|
Fig. 7
from Cox et al., 2016
|
Reporter gene expression
No data available
PHENOTYPE
Phenotype in s705Tg
Phenotype
|
Conditions
|
Figures
|
liver ab5-akt labeling decreased amount, abnormal
|
chemical treatment: sirolimus
|
Fig. 6
from Cox et al., 2016
|
liver ab9-rps6 labeling decreased amount, abnormal
|
chemical treatment: sirolimus
|
Fig. 6
from Cox et al., 2016
|
liver ab5-akt labeling increased amount, abnormal
|
chemical treatment: methionine sulfoximine
|
Fig. 6
from Cox et al., 2016
|
liver ab9-rps6 labeling increased amount, abnormal
|
chemical treatment: methionine sulfoximine
|
Fig. 6
from Cox et al., 2016
|
liver glulb expression increased amount, abnormal
|
standard conditions
|
Fig. 2
from Cox et al., 2016
|
liver ccn1l2 expression increased amount, abnormal
|
standard conditions
|
Fig. 2
from Cox et al., 2016
|
liver amotl2b expression increased amount, abnormal
|
standard conditions
|
Fig. 2
from Cox et al., 2016
|
liver ccn2a expression increased amount, abnormal
|
standard conditions
|
Fig. 2
from Cox et al., 2016
|
liver glula expression increased amount, abnormal
|
standard conditions
|
Fig. 2
from Cox et al., 2016
|
liver increased mass, abnormal
|
control
|
Fig. 7
from Cox et al., 2016
|
liver size, ameliorated
|
chemical treatment: methionine sulfoximine
|
Fig. 7
from Cox et al., 2016
|
liver cell population proliferation increased occurrence, abnormal
|
control
|
Fig. 7
from Cox et al., 2016
|
liver cell population proliferation occurrence, ameliorated
|
chemical treatment: methionine sulfoximine
|
Fig. 7
from Cox et al., 2016
|
liver glutamate-ammonia ligase activity increased occurrence, abnormal
|
standard conditions
|
Fig. 4,
Fig. 7
from Cox et al., 2016
|
liver glutamate-ammonia ligase activity occurrence, ameliorated
|
chemical treatment: methionine sulfoximine
|
Fig. 7
from Cox et al., 2016
|
liver nucleotide biosynthetic process increased occurrence, abnormal
|
control
|
Fig. 7
from Cox et al., 2016
|
liver nucleotide biosynthetic process occurrence, ameliorated
|
chemical treatment: methionine sulfoximine
|
Fig. 7
from Cox et al., 2016
|
whole organism paics expression decreased amount, abnormal
|
control
|
Fig. S4
from Weger et al., 2018
|
CITATIONS (2)